Thienopyridinone compounds and methods of treatment

A method of treating a CNS or peripheral nervous system disorder, comprising administering to a patient in need thereof a pharmaceutical composition comprising a compound of formula II

• wherein
• R1 is a (C1-C8) branched or unbranched alkyl or alkenyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• a substituted or unsubstituted aryl or heteroaryl ring;
• branched or unbranched haloalkyl (e.g., CF3, CF3—CH2, CF3—CF2—);
• or a substituted or unsubstituted (CH2)p-aryl or (CH2)p-heteroaryl ring, where p is 1, 2, 3, or 4;
• and
• R2 is an optionally substituted (C1-C6) branched or unbranched alkyl, alkenyl, alkynyl, alkylhydroxy, alkylalkoxy, or alkylacyl group,
• in an amount effective to treat said CNS or peripheral nervous system disorder.

A method of treating irritable bowel syndrome, comprising administering to a patient in need thereof a pharmaceutical composition comprising a compound of formula II

• wherein
• R1 is a (C1-C8) branched or unbranched alkyl or alkenyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• a substituted or unsubstituted aryl or heteroaryl ring;
• branched or unbranched haloalkyl (e.g., CF3, CF3—CH2, CF3—CF2—);
• or a substituted or unsubstituted (CH2)p-aryl or (CH2)p-heteroaryl ring, where p is 1, 2, 3, or 4;
• and
• R2 is an optionally substituted (C1-C6) branched or unbranched alkyl, alkenyl, alkynyl, alkylhydroxy, alkylalkoxy, or alkylacyl group,
• in an amount effective to treat said CNS or peripheral nervous system disorder.

A method of treating Alzheimer's disease, comprising administering to a patient in need thereof a pharmaceutical composition comprising a compound of formula II

• wherein
• R1 is a (C1-C8) branched or unbranched alkyl or alkenyl;
• a (C1-C8) substituted or unsubstituted carbocyclic ring;
• a substituted or unsubstituted aryl or heteroaryl ring;
• branched or unbranched haloalkyl (e.g., CF3, CF3—CH2, CF3—CF2—);
• or a substituted or unsubstituted (CH2)p-aryl or (CH2)p-heteroaryl ring, where p is 1, 2, 3, or 4;
• and
• R2 is an optionally substituted (C1-C6) branched or unbranched alkyl, alkenyl, alkynyl, alkylhydroxy, alkylalkoxy, or alkylacyl group,
• in an amount effective to treat said CNS or peripheral nervous system disorder.